SEC charges Cassava over 'misleading' Alzheimer's claims
The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former head of neuroscience Dr Lindsay Burns of misleading investors by announcing that the company’s small-molecule therapeutic simufilam significantly improved patient cognition in the phase 2b study.
Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...
The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug ...
Cassava Sciences has agreed to pay $40 million to resolve an investigation into claims it made m | Cassava Sciences has ...
Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...
On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $28.49 which represents a decrease of $-3.38 or -10.61% from the prior close of $31.87. The stock opened at $28.08 and ...
Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback